Recommended Topic Related To:

Fosamax

"Feb. 22, 2011 -- There is new evidence that long-term use of the most widely prescribed bone loss drugs may increase the risk for uncommon but serious femur (thigh bone) fractures.

In an analysis involving more than 200,000 postmenopa"...

Fosamax

Fosamax

Fosamax Side Effects Center

Medical Editor: Charles Patrick Davis, MD, PhD

Tenormin (atenolol) (and Tenormin IV) is a beta blocking drug used mainly for control of hypertension, angina, for management of acute myocardial infarction and occasionally for thyroid storm management. Tenormin is available as generic atenolol in tablets and IV. Side effects of Tenormin may include dizziness, lethargy, mild bradycardia, depression, and mild shortness of breath for both preparations. Patients with bronchospastic disease, in general, should not take Tenormin or other beta-blockers.

Tenormin is available in 25, 50 and 100 mg strength tablets; it is also available vials of 5 mg atenolol in ten ml of citrate-buffered solution for intravenous injection. The IV preparation should only be administered by trained personnel. The usual dose for tablets begins at 25 mg once or twice per day and is modified by patient response to the medication. The following information applies to both the tablet and IV forms of atenolol. Serious side effects of Tenormin may include heart arrhythmias, hypotension, pulmonary emboli, chest pain, and bronchospasm. Use with calcium channel blockers (CCBs) may precipitate bradycardia. This medication should be used during pregnancy only when clearly needed. It may harm an unborn baby. This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult the doctor before breastfeeding. Women taking Tenormin should discuss the risks and benefits with their doctor. Safety and effectiveness has not been established in pediatric patients.

Our Tenormin IV Side Effects Drug Center provide a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Fosamax in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using alendronate and call your doctor at once if you have any of these serious side effects:

  • chest pain;
  • difficulty or pain when swallowing;
  • pain or burning under the ribs or in the back;
  • severe heartburn, burning pain in your upper stomach, or coughing up blood;
  • new or worsening heartburn;
  • fever, body aches, flu symptoms;
  • severe joint, bone, or muscle pain;
  • new or unusual pain in your thigh or hip;
  • jaw pain, numbness, or swelling.

Less serious side effects may include:

  • mild heartburn, bloating;
  • mild nausea, vomiting, or stomach pain;
  • diarrhea, gas, or constipation;
  • mild joint pain or swelling;
  • swelling in your hands or feet; or
  • dizziness, eye pain, headache.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Fosamax (Alendronate Sodium) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Fosamax Overview - Patient Information: Side Effects

SIDE EFFECTS: Stomach pain, constipation, diarrhea, gas, or nausea may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: jaw pain, increased or severe bone/joint/muscle pain, new or unusual hip/thigh/groin pain, swelling of joints/hands/ankles/feet, black/tarry stools, vomit that looks like coffee grounds.

This medication may infrequently cause serious irritation and ulcers of the esophagus. If you notice any of the following unlikely but very serious side effects, stop taking alendronate and talk to your doctor or pharmacist right away: new or worsening heartburn, chest pain, pain or difficulty when swallowing.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Fosamax (Alendronate Sodium)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Fosamax FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Treatment of Osteoporosis in Postmenopausal Women

Daily Dosing

The safety of FOSAMAX in the treatment of postmenopausal osteoporosis was assessed in four clinical trials that enrolled 7453 women aged 44-84 years. Study 1 and Study 2 were identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational n=994); Study 3 was the three-year vertebral fracture cohort of the Fracture Intervention Trial [FIT] (n=2027) and Study 4 was the four-year clinical fracture cohort of FIT (n=4432). Overall, 3620 patients were exposed to placebo and 3432 patients exposed to FOSAMAX. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs were included in these clinical trials. In Study 1 and Study 2 all women received 500 mg elemental calcium as carbonate. In Study 3 and Study 4 all women with dietary calcium intake less than 1000 mg per day received 500 mg calcium and 250 international units Vitamin D per day.

Among patients treated with alendronate 10 mg or placebo in Study 1 and Study 2, and all patients in Study 3 and Study 4, the incidence of all-cause mortality was 1.8% in the placebo group and 1.8% in the FOSAMAX group. The incidence of serious adverse event was 30.7% in the placebo group and 30.9% in the FOSAMAX group. The percentage of patients who discontinued the study due to any clinical adverse event was 9.5% in the placebo group and 8.9% in the FOSAMAX group. Adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either FOSAMAX or placebo are presented in Table 1.

Table 1: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients

  United States/ Multinational Studies Fracture Intervention Trial
FOSAMAX* %
(n=196)
Placebo %
(n=397)
FOSAMAX† %
(n=3236)
Placebo %
(n=3223)
Gastrointestinal
  abdominal pain 6.6 4.8 1.5 1.5
  nausea 3.6 4.0 1.1 1.5
  dyspepsia 3.6 3.5 1.1 1.2
  constipation 3.1 1.8 0.0 0.2
  diarrhea 3.1 1.8 0.6 0.3
  flatulence 2.6 0.5 0.2 0.3
  acid regurgitation 2.0 4.3 1.1 0.9
  esophageal ulcer 1.5 0.0 0.1 0.1
  vomiting 1.0 1.5 0.2 0.3
  dysphagia 1.0 0.0 0.1 0.1
  abdominal distention 1.0 0.8 0.0 0.0
  gastritis 0.5 1.3 0.6 0.7
Musculoskeletal
  musculoskeletal (bone, muscle or joint) pain 4.1 2.5 0.4 0.3
  muscle cramp 0.0 1.0 0.2 0.1
Nervous
System/Psychiatric
  headache 2.6 1.5 0.2 0.2
  dizziness 0.0 1.0 0.0 0.1
Special Senses
  taste perversion 0.5 1.0 0.1 0.0
* 10 mg/day for three years
† 5 mg/day for 2 years and 10 mg/day for either 1 or 2 additional years

Rash and erythema have occurred.

Gastrointestinal Adverse Reactions

One patient treated with FOSAMAX (10 mg/day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin, developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and FOSAMAX were discontinued and the patient recovered. In the Study 1 and Study 2 populations, 49-54% had a history of gastrointestinal disorders at baseline and 54-89% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies. [See WARNINGS AND PRECAUTIONS]

Laboratory Test Findings

In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in approximately 18% and 10%, respectively, of patients taking FOSAMAX versus approximately 12% and 3% of those taking placebo. However, the incidences of decreases in serum calcium to less than 8.0 mg/dL (2.0 mM) and serum phosphate to less than or equal to 2.0 mg/dL (0.65 mM) were similar in both treatment groups.

Weekly Dosing

The safety of FOSAMAX 70 mg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing FOSAMAX 70 mg once weekly and FOSAMAX 10 mg daily. The overall safety and tolerability profiles of once weekly FOSAMAX 70 mg and FOSAMAX 10 mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients in either treatment group are presented in Table 2.

Table 2: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients

  Once Weekly FOSAMAX FOSAMAX
70 mg %
(n=519)
10 mg/day %
(n=370)
Gastrointestinal
  abdominal pain 3.7 3.0
  dyspepsia 2.7 2.2
  acid regurgitation 1.9 2.4
  nausea 1.9 2.4
  abdominal distention 1.0 1.4
  constipation 0.8 1.6
  flatulence 0.4 1.6
  gastritis 0.2 1.1
  gastric ulcer 0.0 1.1
Musculoskeletal
  musculoskeletal (bone, muscle, joint) pain 2.9 3.2
  muscle cramp 0.2 1.1

Prevention of Osteoporosis in Postmenopausal Women

Daily Dosing

The safety of FOSAMAX 5 mg/day in postmenopausal women 40-60 years of age has been evaluated in three double-blind, placebo-controlled studies involving over 1,400 patients randomized to receive FOSAMAX for either two or three years. In these studies the overall safety profiles of FOSAMAX 5 mg/day and placebo were similar. Discontinuation of therapy due to any clinical adverse event occurred in 7.5% of 642 patients treated with FOSAMAX 5 mg/day and 5.7% of 648 patients treated with placebo.

Weekly Dosing

The safety of FOSAMAX 35 mg once weekly compared to FOSAMAX 5 mg daily was evaluated in a one-year, double-blind, multicenter study of 723 patients. The overall safety and tolerability profiles of once weekly FOSAMAX 35 mg and FOSAMAX 5 mg daily were similar.

The adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either once weekly FOSAMAX 35 mg, FOSAMAX 5 mg/day or placebo are presented in Table 3.

Table 3: Osteoporosis Prevention Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients

  Two/Three-Year Studies One-Year Study
FOSAMAX 5 mg/day %
(n=642)
Placebo %
(n=648)
FOSAMAX 5 mg/day %
(n=361)
Once Weekly FOSAMAX 35 mg %
(n=362)
Gastrointestinal
  dyspepsia 1.9 1.4 2.2 1.7
  abdominal pain 1.7 3.4 4.2 2.2
  acid regurgitation 1.4 2.5 4.2 4.7
  nausea 1.4 1.4 2.5 1.4
  diarrhea 1.1 1.7 1.1 0.6
  constipation 0.9 0.5 1.7 0.3
  abdominal distention 0.2 0.3 1.4 1.1
Musculoskeletal
  musculoskeletal (bone, muscle or joint) pain 0.8 0.9 1.9 2.2

Concomitant Use with Estrogen/Hormone Replacement Therapy

In two studies (of one and two years' duration) of postmenopausal osteoporotic women (total: n=853), the safety and tolerability profile of combined treatment with FOSAMAX 10 mg once daily and estrogen ± progestin (n=354) was consistent with those of the individual treatments.

Osteoporosis in Men

In two placebo-controlled, double-blind, multicenter studies in men (a two-year study of FOSAMAX 10 mg/day and a one-year study of once weekly FOSAMAX 70 mg) the rates of discontinuation of therapy due to any clinical adverse event were 2.7% for FOSAMAX 10 mg/day vs. 10.5% for placebo, and 6.4% for once weekly FOSAMAX 70 mg vs. 8.6% for placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 2% of patients treated with either FOSAMAX or placebo are presented in Table 4.

Table 4: Osteoporosis Studies in Men Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 2% of Patients

  Two-year Study One-year Study
FOSAMAX 10 mg/day %
(n=146)
Placebo %
(n=95)
Once Weekly FOSAMAX70 mg %
(n=109)
Placebo %
(n=58)
Gastrointestinal
  acid regurgitation 4.1 3.2 0.0 0.0
  flatulence 4.1 1.1 0.0 0.0
  gastroesophageal reflux disease 0.7 3.2 2.8 0.0
  dyspepsia 3.4 0.0 2.8 1.7
  diarrhea 1.4 1.1 2.8 0.0
  abdominal pain 2.1 1.1 0.9 3.4
  nausea 2.1 0.0 0.0 0.0

Glucocorticoid-Induced Osteoporosis

In two, one-year, placebo-controlled, double-blind, multicenter studies in patients receiving glucocorticoid treatment, the overall safety and tolerability profiles of FOSAMAX 5 and 10 mg/day were generally similar to that of placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either FOSAMAX 5 or 10 mg/day or placebo are presented in Table 5.

Table 5: One-Year Studies in Glucocorticoid-Treated Patients Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients

  FOSAMAX 10 mg/day %
(n=157)
FOSAMAX 5 mg/day %
(n=161)
Placebo %
(n=159)
Gastrointestinal
  abdominal pain 3.2 1.9 0.0
  acid regurgitation 2.5 1.9 1.3
  constipation 1.3 0.6 0.0
  melena 1.3 0.0 0.0
  nausea 0.6 1.2 0.6
  diarrhea 0.0 0.0 1.3
Nervous System/Psychiatric
  headache 0.6 0.0 1.3

The overall safety and tolerability profile in the glucocorticoid-induced osteoporosis population that continued therapy for the second year of the studies (FOSAMAX: n=147) was consistent with that observed in the first year.

Paget's Disease of Bone

In clinical studies (osteoporosis and Paget's disease), adverse events reported in 175 patients taking FOSAMAX 40 mg/day for 3-12 months were similar to those in postmenopausal women treated with FOSAMAX 10 mg/day. However, there was an apparent increased incidence of upper gastrointestinal adverse reactions in patients taking FOSAMAX 40 mg/day (17.7% FOSAMAX vs. 10.2% placebo). One case of esophagitis and two cases of gastritis resulted in discontinuation of treatment.

Additionally, musculoskeletal (bone, muscle or joint) pain, which has been described in patients with Paget's disease treated with other bisphosphonates, was considered by the investigators as possibly, probably, or definitely drug related in approximately 6% of patients treated with FOSAMAX 40 mg/day versus approximately 1% of patients treated with placebo, but rarely resulted in discontinuation of therapy. Discontinuation of therapy due to any clinical adverse events occurred in 6.4% of patients with Paget's disease treated with FOSAMAX 40 mg/day and 2.4% of patients treated with placebo.

Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of FOSAMAX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a Whole: hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with FOSAMAX, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema.

Gastrointestinal: esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications, have also been reported [see DOSAGE AND ADMINISTRATION; WARNINGS AND PRECAUTIONS].

Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported [see WARNINGS AND PRECAUTIONS].

Musculoskeletal: bone, joint, and/or muscle pain, occasionally severe, and incapacitating [see WARNINGS AND PRECAUTIONS]; joint swelling; low-energy femoral shaft and subtrochanteric fractures [see WARNINGS AND PRECAUTIONS].

Nervous System: dizziness and vertigo.

Pulmonary: acute asthma exacerbations.

Skin: rash (occasionally with photosensitivity), pruritus, alopecia, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Special Senses: uveitis, scleritis or episcleritis.

Read the entire FDA prescribing information for Fosamax (Alendronate Sodium) »

A A A

Fosamax - User Reviews

Fosamax User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Fosamax sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Healthy Bones

Get tips and advances in treatment.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations